Takeda goes all in with build-to-buy play, picking up Maverick and its clinic-ready T cell engagers for $525M
As soon as Takeda and Maverick tied the bow on a $125 million pact in 2017, a countdown was set off: The pharma giant — then in the process of overhauling its R&D operations and assembling an immuno-oncology pipeline — had five years to watch and lend a hand in its little biotech partner’s preclinical work on T cell engagers and decide whether to snap it up or not.
It didn’t end up taking that long.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.